342 related articles for article (PubMed ID: 21317625)
1. Comorbidity burden, healthcare resource utilization, and costs in chronic gout patients refractory to conventional urate-lowering therapy.
Wu EQ; Forsythe A; Guérin A; Yu AP; Latremouille-Viau D; Tsaneva M
Am J Ther; 2012 Nov; 19(6):e157-66. PubMed ID: 21317625
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of health care costs and utilization patterns for patients with gout.
Park H; Rascati KL; Prasla K; McBayne T
Clin Ther; 2012 Mar; 34(3):640-52. PubMed ID: 22381710
[TBL] [Abstract][Full Text] [Related]
3. Impact of noncompliance with urate-lowering drug on serum urate and gout-related healthcare costs: administrative claims analysis.
Halpern R; Mody RR; Fuldeore MJ; Patel PA; Mikuls TR
Curr Med Res Opin; 2009 Jul; 25(7):1711-9. PubMed ID: 19485724
[TBL] [Abstract][Full Text] [Related]
4. Disease-related and all-cause health care costs of elderly patients with gout.
Wu EQ; Patel PA; Yu AP; Mody RR; Cahill KE; Tang J; Krishnan E
J Manag Care Pharm; 2008 Mar; 14(2):164-75. PubMed ID: 18331118
[TBL] [Abstract][Full Text] [Related]
5. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
6. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population.
Doshi JA; Cai Q; Buono JL; Spalding WM; Sarocco P; Tan H; Stephenson JJ; Carson RT
J Manag Care Spec Pharm; 2014 Apr; 20(4):382-90. PubMed ID: 24684643
[TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population.
Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G
J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697
[TBL] [Abstract][Full Text] [Related]
8. Cost Comparison of Urate-Lowering Therapies in Patients with Gout and Moderate-to-Severe Chronic Kidney Disease.
Mitri G; Wittbrodt ET; Turpin RS; Tidwell BA; Schulman KL
J Manag Care Spec Pharm; 2016 Apr; 22(4):326-36. PubMed ID: 27023686
[TBL] [Abstract][Full Text] [Related]
9. Burden of chronic obstructive pulmonary disease in Medicare beneficiaries residing in long-term care facilities.
Simoni-Wastila L; Blanchette CM; Qian J; Yang HW; Zhao L; Zuckerman IH; Pak GH; Silver H; Dalal AA
Am J Geriatr Pharmacother; 2009 Oct; 7(5):262-70. PubMed ID: 19948302
[TBL] [Abstract][Full Text] [Related]
10. Factors associated with recurrent hospital admissions for gout: a case-control study.
Hutton I; Gamble G; Gow P; Dalbeth N
J Clin Rheumatol; 2009 Sep; 15(6):271-4. PubMed ID: 19734730
[TBL] [Abstract][Full Text] [Related]
11. Serum urate levels and gout flares: analysis from managed care data.
Sarawate CA; Patel PA; Schumacher HR; Yang W; Brewer KK; Bakst AW
J Clin Rheumatol; 2006 Apr; 12(2):61-5. PubMed ID: 16601538
[TBL] [Abstract][Full Text] [Related]
12. Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective.
Nicholl D; Akhras KS; Diels J; Schadrack J
Curr Med Res Opin; 2010 Apr; 26(4):943-55. PubMed ID: 20163295
[TBL] [Abstract][Full Text] [Related]
13. Healthcare utilization and costs in women diagnosed with endometriosis before and after diagnosis: a longitudinal analysis of claims databases.
Fuldeore M; Yang H; Du EX; Soliman AM; Wu EQ; Winkel C
Fertil Steril; 2015 Jan; 103(1):163-71. PubMed ID: 25455535
[TBL] [Abstract][Full Text] [Related]
14. Economic burden of non-cystic fibrosis bronchiectasis in the first year after diagnosis from a US health plan perspective.
Joish VN; Spilsbury-Cantalupo M; Operschall E; Luong B; Boklage S
Appl Health Econ Health Policy; 2013 Jun; 11(3):299-304. PubMed ID: 23580074
[TBL] [Abstract][Full Text] [Related]
15. Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.
Blanchette CM; Akazawa M; Dalal A; Simoni-Wastila L
Am J Geriatr Pharmacother; 2008 Aug; 6(3):138-46. PubMed ID: 18775388
[TBL] [Abstract][Full Text] [Related]
16. Flare frequency, healthcare resource utilisation and costs among patients with gout in a managed care setting: a retrospective medical claims-based analysis.
Jackson R; Shiozawa A; Buysman EK; Altan A; Korrer S; Choi H
BMJ Open; 2015 Jun; 5(6):e007214. PubMed ID: 26109113
[TBL] [Abstract][Full Text] [Related]
17. A Systematic Review of the Economic and Humanistic Burden of Gout.
Shields GE; Beard SM
Pharmacoeconomics; 2015 Oct; 33(10):1029-47. PubMed ID: 25969152
[TBL] [Abstract][Full Text] [Related]
18. Incremental cost burden to US healthcare payers of atrial fibrillation/atrial flutter patients with additional risk factors.
Amin AN; Jhaveri M; Lin J
Adv Ther; 2011 Oct; 28(10):907-26. PubMed ID: 21971681
[TBL] [Abstract][Full Text] [Related]
19. Burden of illness in idiopathic pulmonary fibrosis.
Collard HR; Ward AJ; Lanes S; Cortney Hayflinger D; Rosenberg DM; Hunsche E
J Med Econ; 2012; 15(5):829-35. PubMed ID: 22455577
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of healthcare costs and utilization for patients with gout: a population-based matched cohort study.
Lee YY; Tang CH; Chen JH; Kuo LN; Ko Y
Curr Med Res Opin; 2018 Apr; 34(4):735-740. PubMed ID: 29243513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
